The American Journal of Managed Care

Key Considerations for Optimizing B-VEC in Dystrophic Epidermolysis Bullosa

Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails ...
Healio

FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa

Please provide your email address to receive an email when new articles are posted on . Recessive dystrophic epidermolysis bullosa is a rare and serious condition. Zevaskyn is the first FDA-approved ...
The American Journal of Managed Care

FDA Approves Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa. The approval is based on the pivotal ...
Nasdaq

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization ...
Monthly Prescribing Reference

Zevaskyn Approved for Recessive Dystrophic Epidermolysis Bullosa

Zevaskyn is supplied as a single-dose of up to 12 cellular sheets consisting of a patient's own viable, gene-modified cells that contain functional copies of the COL7A1 gene, which express collagen 7 ...